Delving into the Latest Updates on Beijing Shimao Dongrui Pharmaceutical Technology Co., Ltd. with Synapse

Overview

This study was based on a phase II dose-finding trial, and weighed the balance between the effectiveness and safety of thrombolytics. Alteplase (Aitongli) was used as a control drug. The safety and effectiveness of a one-time intravenous injection of rhM-tPA in patients with acute ST-segment elevation myocardial infarction were further evaluated by expanding the sample size.

Start Date17 Dec 2013

Sponsor / Collaborator

Beijing Shimao Dongrui Pharmaceutical Technology Co., Ltd.

100 Clinical Results associated with Beijing Shimao Dongrui Pharmaceutical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Beijing Shimao Dongrui Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Deals associated with Beijing Shimao Dongrui Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Shimao Dongrui Pharmaceutical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 30 Aug 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Recombinant human tissue-type plasminogen activator modification(Beijing Shimao Dongrui Pharmaceutical Technology Co Ltd) ( PLG x Plasminogen activators )	ST Elevation Myocardial Infarction More	Pending